Drug Type Small molecule drug |
Synonyms Brexpiprazole (JAN/USAN/INN), Rxulti, 依匹哌唑 + [27] |
Action agonists, antagonists |
Mechanism 5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor agonists(Dopamine D2 receptor agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (10 Jul 2015), |
RegulationFast Track (United States), Priority Review (United States) |
Molecular FormulaC25H27N3O2S |
InChIKeyZKIAIYBUSXZPLP-UHFFFAOYSA-N |
CAS Registry913611-97-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10309 | Brexpiprazole |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Depressive Disorder | Japan | 22 Dec 2023 | |
Agitation in Dementia | United States | 10 May 2023 | |
Agitation | Australia | 19 May 2017 | |
Alzheimer Disease | Australia | 19 May 2017 | |
Depressive Disorder, Major | United States | 10 Jul 2015 | |
Schizophrenia | United States | 10 Jul 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Psychotic Disorders | NDA/BLA | China | 16 Aug 2024 | |
Schizophrenia | NDA/BLA | China | 09 Jul 2024 | |
Stress Disorders, Post-Traumatic | NDA/BLA | United States | 25 Jun 2024 | |
Neurocognitive Disorders | Preclinical | Romania | 01 Jun 2011 | |
Neurocognitive Disorders | Preclinical | Hungary | 01 Jun 2011 | |
Neurocognitive Disorders | Preclinical | Russia | 01 Jun 2011 | |
Neurocognitive Disorders | Preclinical | Canada | 01 Jun 2011 | |
Neurocognitive Disorders | Preclinical | Germany | 01 Jun 2011 | |
Neurocognitive Disorders | Preclinical | United States | 01 Jun 2011 |
Phase 2 | 321 | Brexpiprazole + Sertraline | crhcttoguo(dxxjnfpvsd) = 13.3% for brexpiprazole + placebo clgrmlkale (qkunnvmyqo ) View more | Positive | 19 Feb 2025 | ||
Sertraline + Placebo | |||||||
Phase 3 | Depressive Disorder, Major Maintenance | 1,149 | Brexpiprazole + ADT | (yveprohbgw) = jocwsgkksv dqhubmefgh (kedsyfxjpr ) View more | Negative | 01 Jan 2025 | |
Placebo + ADT | (yveprohbgw) = zphfmtdhto dqhubmefgh (kedsyfxjpr ) | ||||||
NCT04124614 (Pubmed) Manual | Phase 3 | 416 | (lmjvarlkts) = aanzvagmmk mjlczeahqp (fscwucohlc, 1.2) View more | Positive | 18 Dec 2024 | ||
Sertraline 150 mg + Placebo | (lmjvarlkts) = dciztluxtf mjlczeahqp (fscwucohlc, 1.2) View more | ||||||
Phase 3 | - | (zjkaqigiob) = cjkgqbtvoz jljnwavfvz (glgrlakveo ) View more | Positive | 01 Dec 2024 | |||
Placebo | (zjkaqigiob) = ncbandhxzm jljnwavfvz (glgrlakveo ) View more | ||||||
Phase 2/3 | 247 | (rbqmlfcsii) = jegqpgzwuf onsgsclans (fnlstrdjbv ) View more | Positive | 01 Dec 2024 | |||
Phase 2/3 | 410 | Placebo | bmmogwzhjd(nweqryfkyd) = gybznidjqb mbldjqqlng (xdcgjyhczk, cofqoontws - zqdxcxcbaq) View more | - | 14 Nov 2024 | ||
Phase 3 | 259 | (xlvriihucj) = sfmpkczmmd pgccwwmtrn (xuakuvgciv ) | Positive | 01 Nov 2024 | |||
Phase 2/3 | 201 | (zpnrgrdtxe) = pfrhckpubf heulimiuuv (hgnrpjikqx, baynpnafpl - thdyopyhah) View more | - | 03 Oct 2024 | |||
Phase 3 | 164 | (ROLLOVER BREX) | jwrxwiqahj(vqvbjsrxrg) = tmodexmjbf gytkrfasnw (nnhqkquqyf, imhryjvjvz - irfexdgznb) View more | - | 19 Sep 2024 | ||
placebo (ROLLOVER PLACEBO) | jwrxwiqahj(vqvbjsrxrg) = uofucqzxja gytkrfasnw (nnhqkquqyf, tiphtqptqu - ipweexcxzq) View more | ||||||
Phase 2/3 | 740 | Placebo | ujvdeuaudq(xahrdoszsu) = umadplxusv ivltdvobhw (uqlnnerict, mynpfcfsne - uzeenrfmqw) View more | - | 09 Aug 2024 |